PE20030350A1 - Solvatos de clorhidrato de lercanipidina y novedosas formas cristalinas de clorhidrato de lercanidipina que se obtienen a partir de dichos solvatos - Google Patents
Solvatos de clorhidrato de lercanipidina y novedosas formas cristalinas de clorhidrato de lercanidipina que se obtienen a partir de dichos solvatosInfo
- Publication number
- PE20030350A1 PE20030350A1 PE2002000716A PE2002000716A PE20030350A1 PE 20030350 A1 PE20030350 A1 PE 20030350A1 PE 2002000716 A PE2002000716 A PE 2002000716A PE 2002000716 A PE2002000716 A PE 2002000716A PE 20030350 A1 PE20030350 A1 PE 20030350A1
- Authority
- PE
- Peru
- Prior art keywords
- solvates
- hydrochloride
- lercanidipine hydrochloride
- refers
- lercanipidine
- Prior art date
Links
- WMFYOYKPJLRMJI-UHFFFAOYSA-N Lercanidipine hydrochloride Chemical compound Cl.COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 WMFYOYKPJLRMJI-UHFFFAOYSA-N 0.000 title abstract 4
- 229960002162 lercanidipine hydrochloride Drugs 0.000 title abstract 4
- 239000012453 solvate Substances 0.000 title abstract 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 title 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 abstract 6
- -1 3,3-DIPHENYLPROPYL Chemical class 0.000 abstract 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 abstract 2
- 238000002441 X-ray diffraction Methods 0.000 abstract 2
- KFZMGEQAYNKOFK-YZRHJBSPSA-N (214C)propan-2-ol Chemical compound [14CH](C)(C)O KFZMGEQAYNKOFK-YZRHJBSPSA-N 0.000 abstract 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 abstract 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 abstract 1
- 238000001033 granulometry Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000003960 organic solvent Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE REFIERE A CLORHIDRATO DE LERCANIDIPINA [METIL 1,1,N-TRIMETIL-N-(3,3-DIFENILPROPIL)-2-AMINOETIL-1,4-DIHIDRO-2,6-DIMETIL-4-(3-NITROFENIL)PIRIDIN-3,5-DICARBOXILATO] CON SOLVENTES ORGANICOS QUE SE SELECCIONAN DE CLORURO DE METILENO, ACETONA, ANISOL, TETRAHIDROFURANO, METIL-TERBUTIL-ETER, ISOPROPANOL, ENTRE OTROS. LA FORMA CRISTALINA CON CLORURO DE METILENO PRESENTA DIFRACCION DE RAYOS X A LA LONGITUD DE ONDA KO CON UNA d(A) DESDE 2,04 A HASTA 6,6 A; UNA INTENSIDAD RELATIVA DE 29% A 100% Y UN ANGULO (2 0) DESDE 13,4 A 44,4. EL SOLVATO DE FORMA A PRESENTA ASIMISMO RESULTADOS DE DIFRACCION DE RAYO X A LA LONGITUD DE ONDA KO CON UNA d(A) DESDE 2,86 A HASTA 17,4 A, UNA INTENSIDAD RELATIVA DE 29% A 100% Y UN ANGULO (2 0) DESDE 5,1 A 31,3. EL CLORHIDRATO DE LERCANIDIPINA SE PRESENTE EN FORMA MICRONIZADA Y LA GRANULOMETRIAPROMEDIO DE DICHA FORMA ES DE D(50%) 2-8 um, D(90%) MENOR A 15 um. SE REFIERE TAMBIEN A COMPOSICIONES FARMACEUTICAS QUE CONTIENEN ENTRE 1,1 mg A 400mg DE UN AGENTE ACTIVO, DICHAS COMPOSICIONES COMPRENDEN CLORHIDRATO DE LERCANIDIPINA CRISTALINO DE LA FORMA III Y IV. SE REFIERE ADEMAS A UN PROCEDIMIENTO PARA LA PREPARACION
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2001MI001727A ITMI20011727A1 (it) | 2001-08-06 | 2001-08-06 | Solvati della lercanidipina cloridrato e nuove forme cristalline della lercanidipina cloridrato ottenute da essi |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20030350A1 true PE20030350A1 (es) | 2003-06-06 |
Family
ID=11448246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2002000716A PE20030350A1 (es) | 2001-08-06 | 2002-08-06 | Solvatos de clorhidrato de lercanipidina y novedosas formas cristalinas de clorhidrato de lercanidipina que se obtienen a partir de dichos solvatos |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1423367B1 (es) |
| JP (1) | JP2005502648A (es) |
| KR (1) | KR100912664B1 (es) |
| CN (1) | CN100494175C (es) |
| AR (1) | AR037230A1 (es) |
| AT (1) | ATE294162T1 (es) |
| AU (1) | AU2002331390B2 (es) |
| BR (1) | BR0211738A (es) |
| DE (1) | DE60203919D1 (es) |
| EA (1) | EA200400279A1 (es) |
| ES (1) | ES2209684T1 (es) |
| HR (1) | HRP20040157A2 (es) |
| HU (1) | HUP0401161A3 (es) |
| IL (2) | IL153916A0 (es) |
| IT (1) | ITMI20011727A1 (es) |
| MX (1) | MXPA04001073A (es) |
| NO (1) | NO20040479L (es) |
| PE (1) | PE20030350A1 (es) |
| PL (1) | PL369449A1 (es) |
| UY (1) | UY27409A1 (es) |
| WO (1) | WO2003014085A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100651212B1 (ko) | 2004-10-27 | 2006-12-01 | 제일약품주식회사 | 무정형 레르카니디핀의 제조방법 |
| AR052918A1 (es) | 2005-02-25 | 2007-04-11 | Recordati Ireland Ltd | Clorhidrato de lercanidipina amorfo |
| BRPI0616169B8 (pt) * | 2005-09-16 | 2021-05-25 | Glenmark Pharmaceuticals Ltd | cloridrato de lercanidipina na forma polimorfa v, composição farmacêutica compreendendo dito composto e processos para preparação de cloridrato de lercanidipina |
| CN101868442A (zh) * | 2007-03-05 | 2010-10-20 | 阿克塔维什集团Ptc公司 | 盐酸乐卡地平多晶型物和1,1,n-三甲基-n-(3,3-二苯基丙基)-2-氨基乙酰醋酸乙酯的改进制法 |
| WO2008136392A1 (ja) * | 2007-04-27 | 2008-11-13 | Ajinomoto Co., Inc. | 経口投与用製剤 |
| WO2011161223A2 (en) | 2010-06-23 | 2011-12-29 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Pharmaceutical oral dosage forms comprising lercanidipine and enalapril and their pharmaceutically acceptable salts |
| EP2654729B1 (en) | 2010-12-24 | 2016-05-04 | KRKA, d.d., Novo mesto | Homogenous pharmaceutical oral dosage forms comprising lercanidipine and enalapril or their pharmaceutically acceptable salts together with an organic acid |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8403866D0 (en) * | 1984-02-14 | 1984-03-21 | Recordati Chem Pharm | Diphenylalkylaminoalkyl esters |
| US5767136A (en) * | 1995-05-12 | 1998-06-16 | Recordati, S.A. Chemical And Pharmaceutical Company | 1,4-Dihydropyridines useful for prevention or reduction of atherosclerotic lesions on arterial walls |
-
2001
- 2001-08-06 IT IT2001MI001727A patent/ITMI20011727A1/it unknown
-
2002
- 2002-08-02 AR ARP020102957A patent/AR037230A1/es not_active Application Discontinuation
- 2002-08-05 DE DE60203919T patent/DE60203919D1/de not_active Expired - Lifetime
- 2002-08-05 EA EA200400279A patent/EA200400279A1/ru unknown
- 2002-08-05 AT AT02767318T patent/ATE294162T1/de not_active IP Right Cessation
- 2002-08-05 EP EP02767318A patent/EP1423367B1/en not_active Expired - Lifetime
- 2002-08-05 HU HU0401161A patent/HUP0401161A3/hu unknown
- 2002-08-05 IL IL15391602A patent/IL153916A0/xx unknown
- 2002-08-05 KR KR1020047001791A patent/KR100912664B1/ko not_active Expired - Fee Related
- 2002-08-05 ES ES02767318T patent/ES2209684T1/es active Pending
- 2002-08-05 BR BR0211738-0A patent/BR0211738A/pt not_active IP Right Cessation
- 2002-08-05 MX MXPA04001073A patent/MXPA04001073A/es not_active Application Discontinuation
- 2002-08-05 JP JP2003519035A patent/JP2005502648A/ja active Pending
- 2002-08-05 PL PL02369449A patent/PL369449A1/xx unknown
- 2002-08-05 AU AU2002331390A patent/AU2002331390B2/en not_active Ceased
- 2002-08-05 CN CNB028155114A patent/CN100494175C/zh not_active Expired - Fee Related
- 2002-08-05 WO PCT/EP2002/008700 patent/WO2003014085A1/en active IP Right Grant
- 2002-08-06 PE PE2002000716A patent/PE20030350A1/es not_active Application Discontinuation
- 2002-08-06 UY UY27409A patent/UY27409A1/es not_active Application Discontinuation
-
2003
- 2003-01-13 IL IL153916A patent/IL153916A/en unknown
-
2004
- 2004-02-03 NO NO20040479A patent/NO20040479L/no not_active Application Discontinuation
- 2004-02-18 HR HR20040157A patent/HRP20040157A2/hr not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IL153916A (en) | 2008-07-08 |
| EP1423367B1 (en) | 2005-04-27 |
| KR100912664B1 (ko) | 2009-08-17 |
| CN100494175C (zh) | 2009-06-03 |
| HUP0401161A2 (hu) | 2004-09-28 |
| EP1423367A1 (en) | 2004-06-02 |
| HRP20040157A2 (en) | 2004-08-31 |
| CN1538958A (zh) | 2004-10-20 |
| BR0211738A (pt) | 2004-09-28 |
| JP2005502648A (ja) | 2005-01-27 |
| EA200400279A1 (ru) | 2004-06-24 |
| UY27409A1 (es) | 2003-03-31 |
| KR20040030932A (ko) | 2004-04-09 |
| AR037230A1 (es) | 2004-11-03 |
| DE60203919D1 (de) | 2005-06-02 |
| AU2002331390B2 (en) | 2008-06-05 |
| HUP0401161A3 (en) | 2009-04-28 |
| NO20040479L (no) | 2004-02-03 |
| ITMI20011727A1 (it) | 2003-02-06 |
| MXPA04001073A (es) | 2005-02-17 |
| ES2209684T1 (es) | 2004-07-01 |
| ITMI20011727A0 (it) | 2001-08-06 |
| PL369449A1 (en) | 2005-04-18 |
| ATE294162T1 (de) | 2005-05-15 |
| WO2003014085A1 (en) | 2003-02-20 |
| IL153916A0 (en) | 2003-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2218922C2 (ru) | Соединения, имеющие в своей структуре фрагмент производного глюкуроновой кислоты и фрагмент производного глюкозамина, способы получения этих соединений и применение этих соединений | |
| CA2385890A1 (en) | Controlled release compositions comprising nimesulide | |
| NO20085078L (no) | Nye forbindelser | |
| KR970706837A (ko) | 약학 조성물 (pharmaceutical compositions) | |
| AU5669398A (en) | Novel cyclosporin derivatives, method of preparation and pharmaceutical compositions containing them | |
| WO2005118166A3 (en) | Pharmaceutical composition containing irbesartan | |
| WO1998058629A3 (en) | Preparation of pharmaceutical compositions | |
| SG147450A1 (en) | Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof | |
| AP1776A (en) | Reconstitutable parenteral composition containing a cox-2 inhibitor. | |
| PE20030350A1 (es) | Solvatos de clorhidrato de lercanipidina y novedosas formas cristalinas de clorhidrato de lercanidipina que se obtienen a partir de dichos solvatos | |
| HUP0002683A2 (hu) | Terápiás anyagok sejtekhez való eljuttatásának fokozására szolgáló készítmények és módszerek | |
| EP0992509A3 (en) | Novel macrolide derivatives | |
| KR910016332A (ko) | 수난용성 약제를 함유하는 약학 조성물 | |
| CY1105168T1 (el) | Διφασικη συνθεση με τραμαδολη | |
| AR009651A1 (es) | Composicion solubilizante/estabilizante anhidra, emulsionable o microemulsionable en agua, para la solubilizacion de los derivados hidrofobosde n-sulfonil indolina, composicion farmaceutica microemulsionable o emulsionable en medio acuoso, y capsulas farmaceuticas, particularmente blandas | |
| BR0005392A (pt) | Composição de dhea e processo | |
| HK1055675A1 (en) | Method for stabilizing a pharmaceutical preparation | |
| HUP0100564A2 (hu) | Matrix metalloproteináz inhibitorok és ilyeneket tartalmazó gyógyszerkészítmények | |
| PT97164A (pt) | Processo para a estabilizacao de uma preparacao que contenham o composto 4-etil-2-hidroxi-imino-5-nitro-3-hexenamida e de composicoes farmaceuticas que o contenham | |
| EP2066301B1 (en) | Injectable pharmaceutical nimesulide solutions | |
| NO331205B1 (no) | Farmasoytisk sammensetning som fast doseringsform og fremgangsmate for fremstilling derav | |
| CS235524B2 (en) | Method of levonantradole derivatives solubilization | |
| BR0107724A (pt) | Composto, processo para a preparação do mesmo, composição farmacêutica e, uso de um composto | |
| NO20013901L (no) | Umettede kolestanderivater og deres anvendelse for fremstilling av meioseregulerende medikamenter | |
| KR950005312A (ko) | 간질환 치료 및 간기능 개선용 의약조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |